Video

Emerging Data in Non-Clear Cell RCC Treatment

Author(s):

Hans Hammers, MD, PhD,Moshe Ornstein, MD

Hans Hammers, MD, PhD, reviews emerging data on the challenging treatment of non-clear cell renal cell carcinoma.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Regina Barragan-Carrillo, MD
Kathryn E. Beckermann, MD, PhD
Hedyeh Ebrahimi, MD, MPH
Axel Merseburger, MD, PhD
Laurence Albigès, MD, PhD
Charles B. Nguyen, MD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Yousef Zakharia, MD
Nazli Dizman, MD
Adam E. Singer, MD, PhD, health sciences clinical instructor, medicine, division lead, Kidney Cancer, Division of Hematology/Oncology, UCLA Health
Related Content
Casdatifan in ccRCC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 12th 2025

Casdatifan Monotherapy Shows Early Efficacy Signals and Tolerable Safety Profile in Pretreated ccRCC

Oncology Unplugged With Dr Chandler Park
February 26th 2025

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

Cemiplimab Plus Chemotherapy in Advanced/Metastatic Penile Carcinoma | Image Credit: © Katsyarina – stock.adobe.com
March 11th 2025

Cemiplimab Plus Chemotherapy Yields Responses in Advanced/Metastatic Penile Carcinoma

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Tivozanib/Nivolumab in RCC | Image Credit: © Crystal light – stock.adobe.com
March 4th 2025

Tivozanib Preserves QOL From Baseline to Week 24 in ICI-Pretreated RCC

Global Oncology | Image Credit: © Katsyarina – stock.adobe.com
March 3rd 2025

Disparities in RCC Trial Access Illuminate the Need for Global Scientific Collaboration